OncoMed Pharmaceuticals, Inc. Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
10/22/2013 9:45:06 AM
REDWOOD CITY, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported data for four of its five clinical-stage programs at poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013, at the Hynes Convention Center in Boston, MA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by